News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Save the date for the 22nd SIO International Conference
Society for Integrative Oncology/X
Nov 10, 2024, 15:29

Save the date for the 22nd SIO International Conference

Society for Integrative Oncology posted on X:

“Save the date! SIO is excited to partner with Dana Farber Cancer Institute in hosting the 22nd SIO International Conference in beautiful Boston next year on October 27-29, 2025.

Please retweet, make plans and spread the news!”

boston Dana-Farber Cancer Institute SIO 2025 Society for Integrative Oncology
Special Coverage
Science
Jan 23, 2025, 15:52
Pavlos Msaouel: Extreme and unexpected phenotypic plasticity by RMC during EZH2 inhibition
Insight
Jan 23, 2025, 15:43
Nicholas Hornstein: More ctDNA data than you can shake a stick at GI25
Science
Jan 23, 2025, 15:31
Next-generation imaging for evaluation in patients with prostate cancer after biochemical recurrence
Science
Jan 23, 2025, 15:28
Summary of the intrinsic, extrinsic and systemic factors developing ‘cold’ tumors
Blog
Jan 23, 2025, 15:27
Daneen Sekoni: Looking for a Manager, Policy and Advocacy at Cancer Support Community
Insight
Jan 23, 2025, 15:24
International BPDCN Day 2025: Advancing Awareness, Research, and Hope for a Rare Hematologic Cancer
Science
Jan 23, 2025, 15:24
Damir Ivanković: Enablers and barriers in implementing global cancer care efficiency metrics
Blog
Jan 23, 2025, 15:13
The 4th edition of Pediatric Radiation Oncology (Virtual) Course (PedROC 4.0) - The Dorcas Cancer Foundation
Blog
Jan 23, 2025, 15:02
Sachin H. Jain: The healthcare industry’s silent complicity in the face of massive dysfunction
Blog
Jan 23, 2025, 14:53
The PAINT Cancer Awareness and Hope event hosted by Cancer Fight Tanzania
Insight
Jan 23, 2025, 14:52
Debate Highlights Presented by Matti Aapro: Should All HR+/HER2- Metastatic Breast Cancer Patients Receive CDK4/6 Inhibitors in the First Line?
Insight
Jan 23, 2025, 14:43
Prof. Joseph Gligorov at BGICC 2025: Should All HR+/HER2- Metastatic Breast Cancer Patients Receive CDK4/6 Inhibitors in the First Line?